Source-grounded facts extracted from 10x Genomics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
10x Genomics, Inc. reported the first quarter ended March 31, 2026 results: revenue $150.8 million, net income Net loss was $13.5 million. Guidance reaffirmed.
“Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025.”
10x Genomics, Inc. announced a restructuring with charges of between $5.5 million and $6.5 million (approximately 8% of the Company’s global workforce).
“On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company’s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5 million and $6.5 million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025.”
Mathai Mammen resigned as Member of the Board of Directors at 10x Genomics, Inc..
“On October 24, 2024, Mathai Mammen informed the Company of his decision to resign as a member of the Board of Directors”
Adam S. Taich was appointed as Chief Financial Officer at 10x Genomics, Inc..
“On August 8, 2024, the Company announced that Adam S. Taich will be joining the Company as its Chief Financial Officer, effective August 12, 2024, replacing Justin J. McAnear”
Justin J. McAnear resigned as Chief Financial Officer at 10x Genomics, Inc..
“Justin J. McAnear, who on August 6, 2024 notified the Company of his intention to resign and who will continue to provide transition services as an employee of the Company through August 30, 2024.”
Sarah A. Teichmann was appointed as Director at 10x Genomics, Inc..
“On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.”
Alan V. Mateo was appointed as Director at 10x Genomics, Inc..
“appointed Alan V. Mateo to the Board of Directors as a Class II director effective immediately”
10x Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $141.0 million, net income -$59.9 million. Guidance reaffirmed.
“Revenue was $141.0 million for the first quarter of 2024, a 5% increase from $134.3 million for the corresponding prior year period. Gross margin was 66% for the first quarter of 2024, as compared to 73% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix driven by Xenium instruments. Operating expenses were $154.4 million for the first quarter of 2024, a 3% increase from $150.4 million for the corresponding prior year period. This increase was driven by higher legal expenses and costs for facilities and information technology partially offset by lower personnel expenses, including stock-based compensation. Operating loss was $61.5 million for the first quarter of 2024, as compared to $52.0 million for the corresponding prior year period. Operating loss includes $36.1 million of stock-based compensation for the first quarter of 2024, as compared to $42.1 million of stock-based compensation for the corresponding prior year per”
10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, net income Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond. Guidance initiated.
“10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023.”
James Wilbur departed as Chief Commercial Officer at 10x Genomics, Inc..
“On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.”
10x Genomics, Inc. reported the year ended December 31, 2023 results: revenue $618.7 million.
“Revenue of approximately $618.7 million for the year ended December 31, 2023”
10x Genomics, Inc. reported the three months ended December 31, 2023 results: revenue $184.0 million.
“Revenue of approximately $184.0 million for the three months ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.